| Generic name | Belantamab mafodotin-blmf |
| Brand name(s), other common name(s) | Blenrep |
| Drug type | B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate |
| How the drug is given | for injection, for intravenous use |
Indications and Usage
Belantamab mafodotin-blmf is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Side effects needing medical attention
The most common adverse reactions are keratopathy (corneal epithelium change on eye exam), decreased visual acuity, nausea, blurred vision, fever (pyrexia), infusion-related reactions, and fatigue.
WARNING: OCULAR TOXICITY
See full prescribing information for complete boxed warning.
- Blenrep caused changes in the corneal epithelium resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms, such as blurred vision and dry eyes.
- Conduct ophthalmic exams at baseline, prior to each dose, and promptly for worsening symptoms. Withhold BLENREP until improvement and resume, or permanently discontinue, based on severity.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.